Experts and visionaries who share a passion for personalized medicine
Corporate & early-stage president/CEO; Qwest, XO Communications (IPO). Investor and advisor to tech companies with successful IPO and exits; Znode, 2CheckOut, Pinnacle Data Systems, NextLink. Original investor in HealthSpot, Seen Media, and other tech firms.
A true healthcare marketing visionary, Jeff is passionate about empowering healthcare providers with new diagnostic tools that improve patient treatment and outcomes. As President, Jeff defines the company’s overall strategy, vision and position in the pharmacogenetics industry. In addition to his work at ChromoCare, Jeff is co-founder and Vice President of Business Development of Brandperx, managing a rapidly expanding network of over 250,000 healthcare providers nationwide. He is a graduate of Ryerson University in Toronto, Canada with 20 years of experience in marketing for healthcare and consumer brands.
Chief Financial Officer
Michele has served as CFO in several early and later stage technology companies where she led both capital raises and oversaw general accounting. Michele started her career withPriceWaterhouseCoopers before moving into corporate finance. Her Masters degree is from The Ohio State University, and she serves on the board of local nonprofits.
Dr. Fuller is an experienced laboratory executive with expertise in accreditation, quality, and operations in both clinical and relationship testing laboratories. He is board certified by the American Board of Clinical Chemistry (ABCC), and is a graduate of New England College, East Carolina University, and the University of North Carolina where he earned his PhD in Microbiology and Immunology.
Senior Research Scientist
Danxin earned her M.D degree at Fudan University Medical School and her Ph.D. at The Institute of Pharmacology and Toxicology, Academy of Military Medical Science in Beijing, China. She is Lead Research Scientist and Associate Director of The Center for Pharmacogenomics at The Ohio State University. Danxin has published over 60 research papers and had several United State Patent applications on pharmacogenetics biomarkers. Dr. Wang’s research focuses on the pharmacogenomics of drug metabolizing enzymes, membrane transporters and genes involved in the central nervous system and cardiovascular diseases.